This CPB has been revised to state that benralizumab (Fasenra) is considered medically necessary for members with blood eosinophils of 150 cells/μL or higher prior to initiation of therapy (within 12 weeks of initial dosing) who meet criteria. (Previous version stated within 4 weeks of initial dosing).